Balyasny Asset Management
CLPT icon

Balyasny Asset Management’s ClearPoint Neuro CLPT Stock Holding History

Balyasny Asset Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-217,274
Closed -$2.97M – 2957
2025
Q4 		$2.97M Buy
+217,274
New +$4.03M ﹤0.01% 1671
2025
Q2 		– Sell
-51,737
Closed -$615K – 2888
2025
Q1 		$615K Buy
51,737
+34,463
+200% +$536K ﹤0.01% 2198
2024
Q4 		$266K Buy
+17,274
New +$224K ﹤0.01% 2437
2023
Q1 		– Sell
-14,361
Closed -$122K – 2709
2022
Q4 		$122K Buy
+14,361
New +$136K ﹤0.01% 2222

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Balyasny Asset Management's CLPT Position: Q1 2026 in Review

Balyasny Asset Management sold out of ClearPoint Neuro (CLPT) in Q1 2026, closing a stake of 217,274 shares — an estimated $2.97M sold.

Balyasny Asset Management first reported a position in CLPT in Q4 2022 and held it in 4 quarters. The position peaked at $2.97M in Q4 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

  • Balyasny Asset Management reported no remaining ClearPoint Neuro position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 217,274 ClearPoint Neuro shares in Q1 2026, an estimated $2.97M.
  • Balyasny Asset Management first reported a position in ClearPoint Neuro in Q4 2022 and held it in 4 quarters.
  • Balyasny Asset Management's ClearPoint Neuro position peaked at $2.97M in Q4 2025.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.